Aug 12, 2026
Closes
Aug 18, 2026
Jerry - Radiopharmaceuticals *SOLE SOURCE*
Lu-177 vipivotide tetraxetan (PLUVICTO) is a radioligand therapeutic agent to perform the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive and metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy or have received prior taxane-based chemotherapy. See attached file.